Alector

Alector, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering immuno-neurology, a novel therapeutic approach for treating neurodegeneration. Immuno-neurology addresses immune dysfunction as the root cause of various pathologies that drive degenerative brain disorders. The company is developing therapies designed to simultaneously treat these conditions by restoring healthy immune function in the brain. Alector's discovery platform supports the company’s scientific approach, enabling it to advance a broad portfolio of product candidates validated through human genetics, which the company believes will increase the probability of technical success and shorten development timelines. As a result, over the past five years, Alector has identified over 40 immune system targets, advanced more than 10 programs into preclinical studies, and moved two product candidates, AL001 and AL002, into clinical development.